Back to top

Tale of the Tape

Zacks Equity Research

Endocyte (ECYT) in Focus: Stock Tumbles 8.3%
March 28, 2014


Trades from $3
Endocyte, Inc. (ECYT - Analyst Report) saw a big move last session, as the company’s shares fell more than 8.0% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.

Although this slump was obviously disappointing, the company has seen 3 positive revisions and its current year earnings consensus has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for ECYT. So make sure to keep an eye on this stock going forward to see if yesterday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

ECYT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is zero.

Some better-ranked stocks in the healthcare sector include Questcor Pharmaceuticals, Inc. , Grifols, S.A. (GRFS - Snapshot Report) and Lannett Company, Inc. (LCI - Snapshot Report) . All these stocks carry a Zacks Rank #1(Strong Buy).   

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>